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Professor Massimo Morbidelli 
 
Highlights of Contributions to Integrated Continuous Biomanufacturing (ICB) 
 
Massimo Morbidelli has had an outstanding professional and scientific career spanning more 
that 33 years. His research has addressed key scientific issues in a remarkably broad range of 
distinct areas including reaction engineering; catalyst design; polymer chemistry and 
engineering; materials characterization and synthesis; colloids and surface science; modeling of 
physiochemical interactions in separations; development, modeling and design of separation 
processes; process control; and, more recently, cell culture and continuous processing for 
biopharmaceutical manufacturing. With 5 co-authored books, well over 650 publications, and 20 
patents, Massimo is a recognized international expert and a thought leader in many areas. He 
has graduated over 100 PhD students, many of whom have gone on to achieve professional 
excellence in many areas. Beyond academia, Massimo has been intensely involved in directing 
and starting up new industrial ventures, including ChromaCon AG, which is focused on 
continuous chromatography for protein purification, and DataHow AG, which is focused on big 
data analysis in bioprocessing and other industries. 
 
Massimo has made enormous contributions to Integrated and Continuous Biomanufacturing, 
which have been instrumental to the scientific and practical progress of this area during the last 
decade. He is responsible for the invention and development of the Multi Column Solvent 
Gradient Process (MCSGP) process, which applies the concept of simulated continuous 
countercurrent operation to purification processes in the bio-pharmaceutical industry. This 
process has been applied to a growing list of different purifications including capture and 
purification of monoclonal antibodies from cell culture supernatants, purification of bispecific 
antibodies and antibody charge isoforms, recovery of pure peptides (Calcitonin) from crude 
mixtures, the production of omega-3 fatty acid ethyl ester (EPA-EE), the extraction of alpha-1-
Antitrypsin from human plasma, and the separation of mono-pegylated from unpegylated and 
multi-pegylated proteins. Beyond continuous downstream processing, Massimo has also been 
responsible for the conception and development of innovative processes that couple continuous 
upstream and downstream steps for truly integrated and continuous bio-manufacturing. While 
continuous chromatography offers, on its own merits, tremendous advantages in terms of 
productivity and capacity utilization, even greater advantages are obtained when continuous 
chromatography is coupled with continuous upstream production. Massimo’s work has made it 
possible to achieve on a practical scale the end-to-end continuous integrated manufacturing of 
therapeutic proteins by integrating a perfusion bioreactor with continuous chromatographic 
capture chromatographic, followed by continuous viral inactivation, and by a MCSGP system for 
polishing. Such an end-to-end continuous flow integration, without holding tanks and with 
controlled operation is indeed the goal of ICB. Massimo’s contributions have been instrumental 
in making this possible. 
Massimo has recently co-authored (with 2 of his former PhD students) the book: D. Pfister, L. 
Nicoud and M. Morbidelli, Continuous Biopharmaceutical Processes 2018, New York, USA: 
Cambridge University Press. This book brings ICB in sharp focus providing the tools to 
understand, model, and implement continuous bioprocessing. He keeps contributing to 
integrated continuous biomanufacturing through his research, industrial activities, and the 






Previous Award Winner: Konstantin Konstantinov, 2017 
Welcome from the Chairs 
 
It is our great pleasure to welcome you all to Brewster (Cape Cod), Massachusetts, USA 
for Integrated Continuous Bioamufacturing IV. This conference is organized under the 
auspices of the Engineering Conferences International (ECI). ECI is a not-for-profit 
global engineering conferences program, originally established in 1962, that provides 
opportunities for the exploration of problems and issues of concern to engineers and 
scientists from many disciplines. ECI has held more than 2000 conferences covering a 
multitude of leading edge topics that are uniquely cross-disciplinary and have served the 
engineering/scientific community for the past 57 years. 
 
ECI’s Integrated and Continuous Biomanufacturing Conference (ICB) series is the 
world's premiere conference in the area of continuous biomanufacturing. In the recent 
past, impressive technological advances have been made to enable implementation of 
continuous bioprocessing across the biopharmaceutical industry. Accordingly, the focus 
of this conference is to build on this momentum and showcase the case studies for 
implementation for GMP biomanufacturing, automation, digitalization, unit operation 
integration, process development methodologies, and application for advanced therapy 
medicinal products (ATMPs). The program was developed to engage thoughtful 
discussion and will feature oral, poster and workshop sessions, with presenters and 
session chairs from academia and industry with a wide range of experience and from 
many countries around the world. 
 
We would like to thank the industrial sponsors for their generous support. We also would 
like to thank all the board members, session chairs, and dedicated ECI staff for putting 
together a great program. Finally, we would like to thank all the speakers, poster 
authors, and attendees for providing the superb scientific content and look forward to the 
interactions that make this meeting so invaluable and productive. We hope you will enjoy 
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Sunday, October 6, 2019 
 
14:00 – 16:15  Conference Check-in (Upstairs landing in Mansion Ballroom) 
 
16:15 – 16:30  Welcome 
  
16:30 – 17:15  Keynote 
   Advanced manufacturing of complex biologics: A CBER perspective 
   Manuel Osorio, FDA/CBER, USA 
 
17:15 – 17:45  Coffee Break 
 
17:45 – 19:15  Workshop 1:  Regulatory Gaps in Continuous Processing 
   Chairs: Andrew Sinclair, BioPharm Services, United Kingdom 
    Karen Sitney, Boehringer Ingelheim, USA 
 
   Workshop 2:  High-throughput Methodologies for ICB 
   Chairs:  Marcel Ottens, TU Delft, Netherlands 
    Rohan Patill, Sanofi, USA 
 
19:15 – 19:30  Stretch Break 
 
19:30 – 20:15  Reception (Ocean Terrace, weather permitting) 
 
20:15 – 21:30  Dinner 
 
21:30 – 23:00  Social Hour 
 
Room locations and notes 
 
• General Sessions will be in the Mansion Ballroom. 
• Poster Sessions will be in the Carriage House (Addie Nickerson and Roland Nickerson rooms). 
• Workshops on Sunday and Wednesday will be in the Carriage House (Addie Nickerson and 
Samuel Nickerson rooms) 
• Meals will be in the Bay Pines Pavilion with the exception of Tuesday lunch (in the poster session 
room) and the banquet on Wednesday. The banquet will be in the Mansion Ballroom. 
• Audio, still photo and video recording by any device (e.g., cameras, cell phones, laptops, PDAs, 
watches) is strictly prohibited during the technical sessions, unless the author and ECI have 
granted prior permission. 
• Speakers – Please have your presentation loaded onto the conference computer prior to the 
session start (preferably the day before). 
• Speakers – Please leave discussion time as previously directed by your session chair. 
• Please do not smoke at any conference functions. 
• Turn your mobile telephones to vibrate or off during technical sessions. 
• Please write your name on your program so that it can be returned to you if lost or misplaced. 
• After the conference, ECI will send an updated participant list to all participants. Please check 
your listing now and if it needs updating, you may correct it at any time by logging into your ECI 
account. 
• Emergency Contact Information: Because of privacy concerns, ECI does not collect or maintain 
emergency contact information for conference participants.  If you would like to have this 
information available in case of emergency, please use the reverse side of your name badge. 
 
 
Monday, October 7, 2019 
 
07:00 – 08:30  Breakfast  
 
                                       Session 1: Case Studies on Integration of Continuous Operations 
Sponsored by Pfizer 
Chairs:  Suzanne Farid, University College London (UCL), United Kingdom 
             Joseph Shultz, Novartis, Switzerland  
 
08:30 – 08:55 Pushing the closed and continuous boundary: End-to-end ICB at the pilot 
scale 
                                       Kevin Brower, Sanofi, USA 
 
08:55 – 09:20              Performance evaluation of an automated and continuous antibody   
                                       purification process in a side-by-side comparability study 
 Benjamin Maiser, Bayer AG, Germany 
 
09:20 – 09:45 Implementing connected processes at-scale - Challenges and opportunities 
for streamlining operations 
 Mark Brower, Merck & Co., Inc., USA 
 
09:45 – 10:10 Integrated continuous bioprocessing: Costs of goods versus cost of 
development 
 Hanna Mahal, University College London, United Kingdom 
 
10:10 – 10:50 Coffee/Networking Break 
 Sponsored by Sanofi 
 
10:50 – 11:15 iSKID: From integrated pilot scale runs to GMP implementation approach 
 Raquel Orozco, Boehringer Ingelheim, USA 
 
11:15 – 12:00  Keynote 
   Development and future manufacturing of live biologicals 
   John Aunins, Seres Therapeutics, USA 
12:00 – 13:30  Lunch 
                                       Session 2: Beyond CHO and/or Proteins 
Sponsored by GE Healthcare 
Chairs: Manuel Carrondo, iBET, Portugal 
Scott Estes, Codiak Biosciences, USA               
 
13:30 – 13:55 The next generation of therapeutics face dramatic challenges – is ICB an 
answer? 
                                       Joseph Shultz, Novartis, Switzerland 
 
13:55 – 14:20 Complex new modalities require advanced bio manufacturing platforms: 
The case of exosome biotherapeutics 
   Konstantin Konstantinov, Codiak Biosciences, USA 
 
14:20 – 14:45 Design of a periodic counter-current chromatography process for efficient 
oncolytic virus purification 
   Ricardo Silva, iBET, Portugal 
 
 
Monday, October 7, 2019 (continued) 
 
14:45 – 15:10 Continuous mode of production for two classes of defective interfering 
influenza A virus particles as antiviral candidates 
   Marc Hein, Max Plank Magdeburg, Germany 
 
15:10 – 15:35 Towards continuous bioprocessing of lentiviral vectors 
   Sven Ansorge, NRC, Montreal, Canada 
 
15:35 – 16:15  Coffee/Networking Break 
   Sponsored by Sartorius Stedim Biotech GmbH 
 
16:15 – 17:30  Poster Snapshot Session 
 
17:30 – 19:00  Free time 
19:00 – 20:30  Dinner 
20:30 – 22:30  Poster session # 1 
   Sponsored by NIIMBL  




Tuesday, October 8, 2019 
 
07:00 – 08:30  Breakfast  
 
   Session 3: GMP Implementation of ICB Processes 
Sponsored by Genentech 
Chairs:  Nitya Jacob, Amgen, USA 
             Rohan Patil, Sanofi, USA 
 
08:30 – 08:55 The new manufacturing paradigm: Challenges and opportunities of 
integrated continuous bioprocessing 
   Matt Shields, Sanofi, USA 
 
08:55 – 09:20 GMP implementation of connected and continuous process at Amgen 
                                       Art Hewig, Amgen, USA 
 
09:20 – 09:45 Continuous bioprocessing with Ultra-high productivity to expedite 
biologics development 
 Weichang Zhou, WuXi Biologics, China 
 
09:45 – 10:10 Developing a flexible automated continuous downstream processing 
system for research to clinical supply 
 Louise Taylor, CPI, United Kingdom 
 
10:10 – 10:50 Coffee/Networking Break 
 
10:50 – 11:15 GMP design of a single-use integrated continuous bio manufacturing 
system  
 Robert E. Kottmeier, Pfizer, USA 
 
11:15 – 12:00  Keynote 
Application of continuous processing in cell and gene therapy: Current 
state and future opportunities 
   Susan Abu-Absi, bluebird bio, USA 
 
12:00 – 14:00   Lunch & Poster Session #2 
   (Authors of even-numbered posters are asked to stay with their posters) 
14:00 – 14:15  Stretch Break 
14:15 – 19:30  Boat ride to Provincetown and dinner on your own 
Buses will depart the hotel at 14:15 for the transfer to Hyannis where we will 
board the boat. The boat will leave at 15:30 and drop off in Provincetown. There 
will be time to explore the town and have dinner. After dinner, buses will transfer 





Wednesday, October 9, 2019 
 
07:00 – 08:30  Breakfast  
 
Session 4: Digitalization and PAT for ICB 
Sponsored by Sanofi 
Chairs:  Richard Braatz, Massachussetts Institute of Technology, USA 
             Alex Toda, Genentech, USA 
 
08:30 – 08:55 Leveraging development to advance digital and PAT technologies in 
manufacturing  
                                       Rick St. John, Genentech, USA 
 
08:55 – 09:20 Control strategies for integrated continuous bioprocessing 
 Christoph Herwig, TU Wien, Austria 
 
09:20 – 09:45 Digital transformation in bio manufacturing 
 Amos E. Lu, Massachusetts Institute of Technology, USA 
 
09:45 – 10:10 Development of scalable semi-continuous downstream processes 
 Xuankuo Xu, Bristol-Myers-Squibb, USA 
 
10:35 – 11:15 Coffee/Networking Break 
 
Session 5: Validation of ICB Processes 
Chairs:  Ana Azevedo, University of Lisbon, Portugal 
             Raquel Orozco, Boehringer Ingelheim, USA 
 
11:15 – 11:40 Process validation approaches to continuous/connected downstream 
process 
 Huanchun Cui, Novartis Pharma AG, Switzerland 
 
11:40 – 12:05 Continuous virus inactivation using a packed-bed reactor 
Duarte L. Martins, ACIB, Austria 
 
12:05 – 12:30 Continuous viral inactivation: Understanding fundamental mass transfer 
enables simplified virus validation 
   Matthew Brown, Boehringer Ingelheim, USA 
 
12:30 – 12:55 Viral clearance validation for a fully continuous manufacturing process for 
phase 1 studies 
 Maarten Pennings, BiosanaPharma, the Netherlands 
 
12:55 – 13:55 Lunch 
 
Session 6: Methodologies for ICB Process Development 
Sponsored by Amgen 
Chairs:  Lindsay Arnold, MedImmune, USA 
Stefan Hepbildikler, Roche, Germany 
             Gerald Striedner, BOKU, Austria 
 
13:55 – 14:20 Strategy for targeted delivery of key nutrients in high cell density perfusion 
 Veronique Chotteau, KTH Royal Institute of Technology, Sweden 
  
Wednesday, October 9, 2019 (continued) 
 
14:20 – 14:45 Process characterization for dynamic design space development: An 
intensified design of experiment method 
                                       Rui Manuel Freitas Oliveira, New University of Lisbon, Portugal 
 
14:45 – 15:10 High density perfused batch: Robustness and scalability of perfusion 
processes from lab scale to commercial scale 
 David Garcia, Novartis, Switzerland 
 
15:10 – 15:35 Successful scale up of an intensified perfusion process to clinical and 
commercial scales 
 Charles Budde, Sanofi, USA 
 
15:35 – 16:00 Tailor-made aqueous two-phase systems for application in continuous 
separation of potent biomolecules 
 Christoph Brandenbusch, Technical University Dortmund, Germany 
 
16:00 – 16:30  Coffee/ Networking Break  
 
16:30 – 18:00                 Workshop 3:  Business Cases for Integrated and Continuous  
Biomanufacturing  
Chairs: Jessica Molek, GSK, USA 
  Daisie Ogawa, Boehringer Ingelheim Pharma, USA 
 
Workshop 4:  Big Data Analytics for Continuous Manufacturing 
Sponsored by MilliporeSigma 
Chairs: Christian Airiau, Sanofi, USA 
Christoph Herwig, TU WIEN, Austria 
Joseph Horwitz, Amicus Therapeutics, USA 
18:00 – 18:15  Stretch Break 
18:15 – 19:00  2019 ICB Award Lecture (Introduction by Konstantin Konstantinov) 
   Automated continuous integrated manufacturing of monoclonal antibodies 
   Massimo Morbidelli, ETH Zurich, Switzerland 
 
19:00 – 19:45  Free time   
 
19:45 – 20:30                 Reception 
20:30 – 22:30                Conference Banquet and Awards Ceremony 




Thursday, October 10, 2019 
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Engineering Conferences International 
Poster Presentations 
 
1 Exploring metabolic demands of high density CHO-cell cultures 
Matthias Noebel, University of Queensland, Australia 
 
2 Modeling the residence time distribution of an end to end integrated biomanufacturing 
process 
Jure Senčar, University of Natural Resources and Life Sciences, Vienna (BOKU), Austria 
 
3 Experimental design and small-scale model for high-performing perfusion media and 
processes scalable to 50 L bioreactors 
Andreas Castan, GE Healthcare, Sweden 
 
4 Elution profile from periodic counter current capture step as an on-line monitoring and 
control tool for perfusion bioreactors 
Daniel Komuczki, Univerisity of natural resources and LIfe Sciences Vienna (BOKU), Austria 
 
5 Straight-through process development of up and downstream integration of 
monoclonal antibodies production using flocculation, AEX and one pass TFF 
Rimenys J. Carvalho, Federal University of Rio de Janeiro (UFRJ), Brazil 
 
6 Hydrocyclones for single-use perfusion application 
Andreas Castan, GE Healthcare, Sweden 
 
7 Flow-through chromatography as a continuous and integrated purification method 
Shuichi Yamamoto, Yamaguchi University, Japan 
 
8 Development of integrated continuous bioprocessing using Continuous 
Countercurrent Tangential Chromatography (CCTC) platform for capture and polishing 
of monoclonal antibodies 
Oleg Shinkazh, Chromatan, USA 
 
9 Intensifying the manufacture of hiPSC therapy products through metabolic and 
process understanding 
Margarida Serra, iBET, Portugal 
 
10 Inclined plate settlers with novel receiver section as a unit operation for complex 
continuous solid-liquid separation problems 
Hannah Engelmaier, ACIB GmbH, Austria 
 
11 Perfusion microbioreactor with integrated cell retention device 
Amer Al-Lozi, MilliporeSigma, USA 
 
12 Decreasing drug development timeline via upstream process intensification 
Daisie Ogawa, Boehringer Ingelheim, USA 
 
13 Virus reduction filtration in continuous bioprocessing: Critical flux concept for virus 
breakthrough 
Dharmesh Kanani, Teva Branded Pharmaceutical Products R&D, Inc, USA 
 
14 Novel periodic alternating tangential filtration harvest approach provides incresed 
volumetric productivity 
Sean Cole, Amgen, USA 
 
 
15 Manipulations of antibody galactosylation in a fed-batch adapted perfusion process 
Mao-shih Liang, Teva Pharmaceuticals, USA 
 
16 Development of scale-down models for validation of integrated continuous virus 
filtrations 
Julie Kozaili, Asahi Kasei Bioprocess, USA 
 
17 Continuous integrated biologics manufacturing 
John Welsh, Pall Life Sciences, United Kingdom 
 
18 Perfusion process for the production of a new, VLP-based yellow fever vaccine 
candidate 
Renata G. F. Alvim, Federal University of Rio de Janeiro (UFRJ), Brazil 
 
19 Critical quality attributes (CQAs) of a therapeutic antibody produced from integrated 
continuous bioprocessing 
I-Fen Liu, Development Center for Biotechnology, Taiwan 
 
20 Process simulation based decisional tool to evaluate strategies for continuous 
downstream bioprocess implementation - A CDMO perspective 
Kristina R. Pleitt, Patheo, USA 
 
21 High cell density optimization strategies for continuous bioprocesses using perfusion 
bioreactors 
Jana Mahadevan, MilliporeSigma, USA 
 
22 Continuous process performance enhancements for 50 L to 500 L single-use 
bioreactors: A technical comparison of erformance characterization, cell culture, and 
scale-up modeling 
Tony Hsiao, Thermo Fisher Scientific, USA 
 
23 Apply adsorption technology to solve the UV sensor instability of dynamic control on 
periodic counter current purification system 
Wei-Kuang Chi, Development Center for Biotechnology, Taiwan 
 
24 Acoustic Wave Separation – A non-filtration approach for continuous clarification of 
perfusion cell culture prior to capture chromatography 
Peter Levison, Pall Biotech, United Kingdom 
 
25 Production of Zika virus-like particles (VLPs) by perfusion processes 
Renata G. F. Alvim, Federal University of Rio de Janeiro (UFRJ), Brazil 
 
26 Integration of upstream and downstream for a hybrid continuous process development 
and manufacturing for a stable monoclonal antibody produced in CHO cell culture 
Jianlin Xu, Bristol-Myers Squibb, USA 
 
27 Conversion of biomanufacturing processes from fed-batch into integrated continuous: 
Strategy, methods and case studies 
Ying Jing, Novartis Pharma, Switzerland 
 
28 Continuous downstream process development following quality by design philosophy 
Marc Bisschops, Pall Biotech, Netherlands 
 
29 Evaluation of ambr® 250 perfusion bioreactor system as a model for high-throughput 
perfusion cell culture process development 
Jack Huang, Merck & Co., Inc, USA 
30 Upstream process intensification using frozen high cell density intermediates 
Luis Fernando Ayala Solares, Merck KGaA, Germany 
 
31 Validation aspects in the commercialization of integrated continuous biomanufacturing 
Canghai Lu, Sanofi, USA 
 
32 Direct inoculation of a perfusion bioreactor with a frozen intermediate seed train 
Sofie Goetschalckx, Sanofi, Belgium 
 
33 A Virus Harvest Unit for the continuous harvesting of lentivirus from suspension cell 
cultures 
Maurizio Cattaneo, Artemis Biosystems, USA 
 
34 Definition of a platform continuous capture scale down model and link to scale-up for 
monoclonal antibody clinical manufacturing 
Rebecca A. Chmielowski, Merck, USA 
 
35 Optimization study on periodic counter-current chromatography (PCC) integrated in a 
mAb downstream process 
Joaquin Gomis Fons, Lund University, Sweden 
 
36 Flow-velocity programmed chromatography as an alternative method for increasing the 
efficiency of continuous- or integrated-chromatography processes 
Chyi-Shin Chen, Yamaguchi University, Japan 
 
37 Continuous aqueous two-phase system extraction using oscillatory flow reactor 
Diogo Faria, Instituto Superior Técnico, Portugal 
 
38 Analytical and data strategy for continuous downstream manufacturing 
Mehdi Ghodbane, GlaxoSmithKline, USA 
 
39 Accelerated process development for integrated end-to-end biologics manufacturing 
Laura E. Crowell, Massachusetts Institute of Technology, USA 
 
40 The NevoLineTM manufacturing system: Intensification & integration of upstream and 
downstream processing in a low-footprint, automated platform for viral production 
Tania Pereira Chilima, Univercells, Belgium 
 
41 Integration of XCellTM ATF perfusion with single column capture chromatography for 
production of monoclonal antibodies 
Amit Dutta, Repligen Corporation, USA 
 
42 Model-based evaluation and process development of continuous chromatography 
Dong-Qiang Lin, Zhejiang University, China 
 
43 Developing new perfusion capabilities for ambr(R) micro and mini bioreactors 
Barney Zoro, Sartorius, United Kingdom 
 
44 Leveraging Sanofi intensified ICB platform to enable early process development for a 
labile and hard-to-express molecule 
Jiuyi Lu, Sanofi, USA 
 
45 Development of scale down models for perfusion bioreactor medium optimization 
Meghan E. Casey, Regeneron, USA 
 
 
46 Introduction of intensified processes into the clinical supply center 
Constanze Duerr, Roche Diagnostics GmbN, Germany 
 
47 Development of an N-1 perfusion medium to intensify seed train operation 
Luis Fernando Ayala Solares, Merck KGaA, Germany 
 
48 A CDMO perspective toward the implementation of continuous bioprocessing stand-
alone and integrated offerings 
Claudia Berdugo-Davis, Catalent Biologics, USA 
 
49 Small-scale end-to-end mAb platform with a continuous and integrated design 
Hubert Schwarz, KTH, Sweden 
 
50 Novel amino acid feeding strategy in perfusion cultures to enhance monoclonal 
antibody production 
Hubert Schwarz, KTH, Sweden 
 
51 Continuous antibody capture step based on Magnetic Beads 
Nils Arnold Brechmann, AdBIOPRO, Competence Centre for Advanced BioProduction by 
Continuous Processing, Sweden 
 
52 Implementation of an integrated continuous downstream process for a monoclonal 
antibody production 
Wei (Heidi) Gong, Shanghai Henlius Biotech, Inc., China 
 
 
